Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase ; volume:132 ; number:49 ; year:2020 ; pages:22247-22255 ; extent:9
Angewandte Chemie ; 132, Heft 49 (2020), 22247-22255 (gesamt 9)
- Urheber
-
Zhao, Chenglong
Weber, Stefan
Schols, Dominique
Balzarini, Jan
Meier, Chris
- DOI
-
10.1002/ange.202003073
- URN
-
urn:nbn:de:101:1-2022053006410249634482
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:40 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhao, Chenglong
- Weber, Stefan
- Schols, Dominique
- Balzarini, Jan
- Meier, Chris
Ähnliche Objekte (12)
Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
Stereoselective synthesis of carbocyclic nucleoside analogues and their triphosphate prodrugs : synthesis of γ-alkyl-modified nucleoside thriphosphates
HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
Lipophilic Nucleoside Triphosphate Prodrugs of Anti‐HIV Active Nucleoside Analogs as Potential Antiviral Compounds
The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)
Efficacy and tolerability of long-term nevirapine plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations
Evaluation and optimisation of nucleoside triphosphate analogues as antiviral prodrugs
Molecular docking analysis of novel Non-Nucleoside Reverse Transcriptase Inhibitors in development: implication for rational drug design
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
Stereoselective synthesis of carbocyclic nucleoside analogues and their triphosphate prodrugs : synthesis of γ-alkyl-modified nucleoside thriphosphates
HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
Lipophilic Nucleoside Triphosphate Prodrugs of Anti‐HIV Active Nucleoside Analogs as Potential Antiviral Compounds
The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)
Efficacy and tolerability of long-term nevirapine plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations
Evaluation and optimisation of nucleoside triphosphate analogues as antiviral prodrugs
Molecular docking analysis of novel Non-Nucleoside Reverse Transcriptase Inhibitors in development: implication for rational drug design
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
Stereoselective synthesis of carbocyclic nucleoside analogues and their triphosphate prodrugs : synthesis of γ-alkyl-modified nucleoside thriphosphates
HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
Lipophilic Nucleoside Triphosphate Prodrugs of Anti‐HIV Active Nucleoside Analogs as Potential Antiviral Compounds
The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)
Efficacy and tolerability of long-term nevirapine plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations
Evaluation and optimisation of nucleoside triphosphate analogues as antiviral prodrugs
Molecular docking analysis of novel Non-Nucleoside Reverse Transcriptase Inhibitors in development: implication for rational drug design
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells